{"id":87670,"date":"2018-10-09T10:26:48","date_gmt":"2018-10-09T07:26:48","guid":{"rendered":"http:\/\/mylivia.com\/?page_id=87670"},"modified":"2018-10-30T16:28:58","modified_gmt":"2018-10-30T14:28:58","slug":"clinical","status":"publish","type":"page","link":"https:\/\/mylivia.com\/clinical\/","title":{"rendered":"Clinical"},"content":{"rendered":"<p style=\"text-align: center;\"><b>A <\/b><b>Randomized<\/b><b>, Controlled, Multi-center, <\/b><b>Crossover<\/b><b>, Prospective, Double-blind Clinical Study To Assess The <\/b><b>Effectiveness And Safety <\/b><b>Of<\/b><u><b><br \/>\n<\/b><\/u><b>Livia\u00ae\u00a0<\/b><b><i><br \/>\n<\/i><\/b><b>In Women Suffering From Primary Dysmenorrhea<\/b><\/p>\n<h3><\/h3>\n<p><b>To evaluate:<\/b><\/p>\n<p><b>Safety and efficacy of Livia vs. Sham<\/b><\/p>\n<p>non-stimulated device on Dysmenorrhea (painful menstruation) symptoms in menstruating women<\/p>\n<h4><\/h4>\n<p>&nbsp;<\/p>\n<h4>Eligible subjects randomly assigned in a 1:1 ratio to one of 2 sequences:<\/h4>\n<ul>\n<li>\n<h4><b>Sequence A<\/b> = Use of the Livia device during the first study cycle (Menstrual Period (MP)) and a sham device during the second study cycle.<\/h4>\n<\/li>\n<li>\n<h4><b>Sequence B<\/b> = Use of a sham device during the first study cycle and Livia device during the second study cycle.<\/h4>\n<\/li>\n<\/ul>\n<h4><\/h4>\n<h4><\/h4>\n<p>&nbsp;<\/p>\n<h4><b>Endpoints<\/b><\/h4>\n<h4><b>PRIMARY EFFICACY ENDPOINT:<\/b><\/h4>\n<h4>The primary efficacy endpoint of the study is to evaluate the difference between the reported Visual Analogue Scale (VAS) before and after applying the device (active or sham).<\/h4>\n<h4><\/h4>\n<p>&nbsp;<\/p>\n<h4><b>SAFETY AND TOLERABILITY ENDPOINTS:<\/b><\/h4>\n<h4>The safety and tolerability endpoints of this study are:<\/h4>\n<ul>\n<li>\n<h4>Adverse events (AEs) and serious adverse events (SAEs)<\/h4>\n<\/li>\n<li>\n<h4>Duration of use of the device<\/h4>\n<\/li>\n<\/ul>\n<h4><\/h4>\n<p>&nbsp;<\/p>\n<h4><b>SECONDARY EFFICACY ENDPOINT:<\/b><\/h4>\n<ul>\n<li>\n<h4>Usage of pain relievers during the menstrual period as recorded in the subjects&#8217; diaries. This will be measured by the number of pain relief pills taken during the entire menstrual period.<\/h4>\n<\/li>\n<li>\n<h4>Quality of life will be assessed using the Q-LES Questionnaire. The summary score will be determined as per the questionnaire manual.<\/h4>\n<\/li>\n<li>\n<h4>The convenience of device operation and usage will be determined using a series of specific questions posed to the subjects at visit 3.<\/h4>\n<\/li>\n<\/ul>\n<h4><\/h4>\n<h4><\/h4>\n<p>&nbsp;<\/p>\n<h4>Subjects in the study experienced a decline in pain as assessed by the Visual Analogue Scale (VAS).<\/h4>\n<h4>The use of Livia device succeeded in reducing the VAS score by an average of 28.1 points.<\/h4>\n<h4>The use of Sham device reduced the VAS score by 17.6 points.<\/h4>\n<h4><b>A statistically significant difference between Livia and Sham was observed (P&lt;0.0001).<\/b><\/h4>\n<h4><\/h4>\n<h4><\/h4>\n<p>&nbsp;<\/p>\n<h4>Analysis of reduction in VAS was also carried out separately for each treatment sequence:<\/h4>\n<ul>\n<li>\n<h4>Livia caused a greater reduction in VAS in sequence A (first Livia, then sham)<\/h4>\n<\/li>\n<li>\n<h4>Sham caused a greater reduction in VAS in sequence B (first sham, then Livia).<\/h4>\n<\/li>\n<\/ul>\n<h4>Therefore, statistically significant reduction in VAS was observed only in sequence A (P&lt;0.0001) but not in the sequence B (P=0.3923).<\/h4>\n<h4><\/h4>\n<p>&nbsp;<\/p>\n<h4>Secondary analyses evaluated the use of pain relief pills, quality of life (QoL) and device usability.<\/h4>\n<ul>\n<li>\n<h4>Most subjects used pain relief pills once or twice per cycle in all treatments and treatment sequences.<\/h4>\n<\/li>\n<li>\n<h4>The QoL score was higher in both sequence treatment groups compared to Baseline. The improvement in QoL was higher in sequence A (first Livia, then sham) compared to sequence B (first sham, then Livia).<\/h4>\n<\/li>\n<li>\n<h4>Usability of the device received good scores by users and no technical problems were detected.<\/h4>\n<\/li>\n<\/ul>\n<h4><b><\/b><u><b><br \/>\n<\/b><\/u><\/h4>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A Randomized, Controlled, Multi-center, Crossover, Prospective, Double-blind Clinical Study To<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"page-contact.php","meta":[],"yst_prominent_words":[258,174,265,175,262,263,266,170,177,172,171,267,173,261,260,176,264,259,257,169],"_links":{"self":[{"href":"https:\/\/mylivia.com\/wp-json\/wp\/v2\/pages\/87670"}],"collection":[{"href":"https:\/\/mylivia.com\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/mylivia.com\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/mylivia.com\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/mylivia.com\/wp-json\/wp\/v2\/comments?post=87670"}],"version-history":[{"count":0,"href":"https:\/\/mylivia.com\/wp-json\/wp\/v2\/pages\/87670\/revisions"}],"wp:attachment":[{"href":"https:\/\/mylivia.com\/wp-json\/wp\/v2\/media?parent=87670"}],"wp:term":[{"taxonomy":"yst_prominent_words","embeddable":true,"href":"https:\/\/mylivia.com\/wp-json\/wp\/v2\/yst_prominent_words?post=87670"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}